Non-alcoholic fatty liver disease: An early mediator predicting metabolic syndrome in obese children? 2011

Jun-Fen Fu, and Hong-Bo Shi, and Li-Rui Liu, and Ping Jiang, and Li Liang, and Chun-Lin Wang, and Xi-Yong Liu
Department of Endocrinology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China. fjf68@yahoo.com.cn

OBJECTIVE To investigate if non-alcoholic fatty liver disease (NAFLD) is an early mediator for prediction of metabolic syndrome, and if liver B-ultrasound can be used for its diagnosis. METHODS We classified 861 obese children (6-16 years old) into three subgroups: group 0 (normal liver in ultrasound and normal transaminases); group 1 (fatty liver in ultrasound and normal transaminases); and group 2 (fatty liver in ultrasound and elevated transaminases). We measured the body mass index, waist and hip circumference, blood pressure, fasting blood glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), whole-body insulin sensitivity index (WBISI), lipid profile and transaminases in all the participants. The risk of developing metabolic syndrome (MS) was assessed according to the degree of liver fatty infiltration based on the B-ultrasound examination. RESULTS Among the 861 obese children, 587 (68.18%) were classified as having NAFLD, and 221 (25.67%) as having MS. The prevalence of MS in NAFLD children (groups 1 and 2) was 37.64% (221/587), which was much higher than that in non-NAFLD group (group 0, 12.04%) (P < 0.01). There were significantly higher incidences concerning every component of MS in group 2 compared with group 0 (P < 0.05). The incidence of NAFLD in MS patients was 84.61% (187/221), which was significantly higher than that of hypertension (57.46%, 127/221) and glucose metabolic anomalies (22.62%, 50/221), and almost equal to the prevalence of dyslipidemia (89.14%, 197/221). Based on the B-ultrasound scales, the presence of moderate and severe liver fatty infiltration carried a high risk of hypertension [odds ratio (OR): 2.18, 95% confidence interval (95% CI): 1.27-3.75], dyslipidemia (OR: 7.99, 95% CI: 4.34-14.73), impaired fasting glucose (OR: 3.65, 95% CI: 1.04-12.85), and whole MS (OR: 3.77; 95% CI: 1.90-7.47, P < 0.01). The state of insulin resistance (calculated by HOMA-IR and WBISI) deteriorated as the degree of fatty infiltration increased. CONCLUSIONS NAFLD is not only a liver disease, but also an early mediator that reflects metabolic disorder, and liver B-ultrasound can be a useful tool for MS screening.

UI MeSH Term Description Entries
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005234 Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS. Liver Steatosis,Steatohepatitis,Steatosis of Liver,Visceral Steatosis,Liver Steatoses,Liver, Fatty,Steatohepatitides,Steatoses, Liver,Steatoses, Visceral,Steatosis, Liver,Steatosis, Visceral,Visceral Steatoses
D005260 Female Females
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Jun-Fen Fu, and Hong-Bo Shi, and Li-Rui Liu, and Ping Jiang, and Li Liang, and Chun-Lin Wang, and Xi-Yong Liu
October 2011, World journal of gastroenterology,
Jun-Fen Fu, and Hong-Bo Shi, and Li-Rui Liu, and Ping Jiang, and Li Liang, and Chun-Lin Wang, and Xi-Yong Liu
January 2011, Journal of pediatric endocrinology & metabolism : JPEM,
Jun-Fen Fu, and Hong-Bo Shi, and Li-Rui Liu, and Ping Jiang, and Li Liang, and Chun-Lin Wang, and Xi-Yong Liu
May 2020, Pediatric gastroenterology, hepatology & nutrition,
Jun-Fen Fu, and Hong-Bo Shi, and Li-Rui Liu, and Ping Jiang, and Li Liang, and Chun-Lin Wang, and Xi-Yong Liu
October 2020, Hong Kong medical journal = Xianggang yi xue za zhi,
Jun-Fen Fu, and Hong-Bo Shi, and Li-Rui Liu, and Ping Jiang, and Li Liang, and Chun-Lin Wang, and Xi-Yong Liu
January 2014, Obesity research & clinical practice,
Jun-Fen Fu, and Hong-Bo Shi, and Li-Rui Liu, and Ping Jiang, and Li Liang, and Chun-Lin Wang, and Xi-Yong Liu
January 2009, Annals of hepatology,
Jun-Fen Fu, and Hong-Bo Shi, and Li-Rui Liu, and Ping Jiang, and Li Liang, and Chun-Lin Wang, and Xi-Yong Liu
January 2009, Hippokratia,
Jun-Fen Fu, and Hong-Bo Shi, and Li-Rui Liu, and Ping Jiang, and Li Liang, and Chun-Lin Wang, and Xi-Yong Liu
January 2012, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association,
Jun-Fen Fu, and Hong-Bo Shi, and Li-Rui Liu, and Ping Jiang, and Li Liang, and Chun-Lin Wang, and Xi-Yong Liu
January 2007, Current pharmaceutical design,
Jun-Fen Fu, and Hong-Bo Shi, and Li-Rui Liu, and Ping Jiang, and Li Liang, and Chun-Lin Wang, and Xi-Yong Liu
July 2007, European journal of clinical nutrition,
Copied contents to your clipboard!